The ubiquitin-proteasome system may be involved in the pathogenesis of hypertrophic cardiomyopathy

Cardiovascular Research

Volumn 66, Issue 1, 2005, Pages 1-3

  Vosberg, Hans Peter ^a,b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

EDITORIAL; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ANALYSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORBIDITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SARCOMERE;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIUM; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; UBIQUITIN;

EID: 14844355855     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.02.002     Document Type: Editorial

References (14)

1. A.J. Marian Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathies Lancet 355 2000 58 60
2. D. Fatkin, and R.M. Graham Molecular mechanisms of inherited cardiomyopathies Physiol. Rev. 82 2002 945 980
3. B.J. Maron Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy Cardiol. Rev. 10 2002 173 181
4. L. Thierfelder, H. Watkins, C. MacRae, R. Lamas, W. McKenna, and H.P. Vosberg α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere Cell 77 1994 701 712
5. B.J. Wilkins, Y.S. Dai, O.F. Bueno, S.A. Parsons, J. Xu, and D.M. Plank Calcineurin/NFAT coupling participates in pathological, but not physiological cardiac hypertrophy Circ. Res. 94 2004 110 118
6. + channels Cardiovasc. Res. 57 2003 320 332
7. A. Sarikas, L. Carrier, C. Schenke, D. Doll, J. Flavigny, and K.S. Lindenberg Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants Cardiovasc. Res. 66 2005 33 44
8. P. Richard, P. Charron, L. Carrier, C. Ledeuil, T. Cheav, and C. Pichereau Hypertrophic cardiomyopathy-distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy Circulation 107 2003 2227 2232
9. G. Kunst, K.R. Kress, M. Gruen, D. Uttenweiler, M. Gautel, and R.H. Fink Myosin binding protein C, a phosphorylation-dependent force regulator that controls the attachment of myosin heads by its interaction with myosin S2 Circ. Res. 86 2000 51 58
10. S.P. Harris, E. Rostkova, M. Gautel, and R.L. Moss Binding of myosin binding protein-C to myosin subfragment S2 affects contractility independent of a tether mechanism Circ. Res. 95 2004 930 936
11. Q. Yang, A. Sanbe, H. Osinska, T.E. Hewett, R. Klevitsky, and J. Robbins A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy J. Clin. Invest. 102 1998 1292 1300
12. Q. Yang, A. Sanbe, H. Osinska, T.E. Hewett, R. Klevitsky, and J. Robbins In vivo modelling of myosin binding protein C familial hypertrophic cardiomyopathy Circ. Res. 85 1999 841 847
13. J.A. Moolman, S. Reith, K. Uhl, S. Bailey, M. Gautel, and B. Jeschke A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance Circulation 101 2000 1396 1400
14. J. Herrmann, A. Ciechanover, L.O. Lerman, and A. Lerman The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended Cardiovasc. Res. 61 2004 11 21